Decheng Capital China Life Sciences USD Fund III, L.P. 4
4 · ALPINE IMMUNE SCIENCES, INC. · Filed Sep 27, 2022
Insider Transaction Report
Form 4
Transactions
- Award
Common Stock
2022-09-23$7.35/sh+639,456$4,700,002→ 5,347,744 total - Award
Common Stock
2022-09-23$7.35/sh+1,360,544$9,999,998→ 1,360,544 total(indirect: See footnote)
Footnotes (2)
- [F1]The reportable securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Xiangmin Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. GP III disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. Dr. Cui is a director of the Issuer and files separate Section 16 reports.
- [F2]The reportable securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healtchcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Xiangmin Cui is the indirect managing member and ultimate beneficial owner of Healthcare GP. Each of Healthcare, Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Healthcare GP disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. Dr. Cui is a director of the Issuer and files separate Section 16 reports.